Vietnam Dermatology Drugs Market Analysis Report 2022 to 2030

Vietnam Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Vietnam Dermatology drugs market will reach a value of $xx Mn from $85 Mn in 2022, growing at a CAGR of xx% during 2022-30. The market is primarily dominated by local players such as Traphaco, Pymepharco, and Imexpharm. The market is driven by the prevalence of dermatology conditions, awareness about dermatological health, and increasing healthcare spending. The dermatology drug market in Vietnam is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.

ID: IN10VNPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Dr. Vishwa Modhia

Buy Now

Vietnam Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the Vietnam Dermatology drugs market will reach a value of $xx Mn from $85 Mn in 2022, growing at a CAGR of xx% during 2022-30.

Vietnam joined the International Association of Dermatologists as a recognized member in 2010. In Vietnam, acne is one of the most prevalent skin conditions, affecting a sizable portion of the populace, especially teenagers and young adults.

Psoriasis and eczema also affect a smaller but still sizable portion of the population and are other common skin conditions in the nation. In Vietnam, population growth and economic development are driving up demand for healthcare services. The cost of healthcare in Vietnam was roughly $17 billion in 2018 (6.6% of GDP). The rise in citizen insurance coverage is the main reason for the anticipated increase in private healthcare spending.

vietnam dermatology drugs market analysis

Market Dynamics

Market Growth Drivers

Spending on dermatology health has increased in Vietnam over the past few years due to factors like rising disposable income, increased awareness of skincare, and an increase in the prevalence of skin conditions like acne and eczema.

Market Restraints

Exporters with little industry experience should avoid Vietnam. Making progress on the commercial front can take a year or two. While the south is the main center of industry, the north has a higher concentration of regulatory and government ministries. The consumer behavior and preferences in the two markets are also different. The market's extreme price sensitivity is another difficulty. Young people with lower incomes make up a sizable portion of the consumer population, and they frequently choose lower-end goods over high-end ones.

Competitive Landscape

Key Players

Imexpharm (VNM)
Pymepharco (VNM)
Traphaco (VNM)
FPT Pharmaceuticals (VNM)
DHG Pharmaceutical (VNM)
GlaxoSmithKline
Pfizer
Sanofi
Johnson & Johnson

Healthcare Regulations and Reimbursement Policies

The Vietnamese Drug Administration oversees pharmaceutical supplements. The Ministry of Health (MOH) is the regulatory body in charge of regulating the dermatology drug market in Vietnam. The MOH is in charge of establishing guidelines for the nation's pharmaceutical product production, importation, and distribution. To guarantee that dermatology medications are secure, efficient, and of the highest caliber, the MOH also collaborates with other pertinent institutions like the National Institute of Drug Quality Control and the National Medical Products Administration. The MOH is also in charge of keeping an eye on and enforcing adherence to the rules and requirements that are relevant to Vietnam's dermatology drug industry.

Under Vietnam's social health insurance program, known as the Vietnam Social Insurance (VSI) program, dermatology medications may be eligible for reimbursement. Prescription drugs are among the medical services and treatments that are covered by the VSI program. However, depending on the particular health insurance plan and the unique circumstances of the patient, both the specific medications that qualify for reimbursement and the amount that is available can change.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.